Hongxu Pu

Dr. Hongxu Pu

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
MZMeng Zheng
Meng Zheng
YZYuanli Zhu
Yuanli Zhu
KWKang Wei
Kang Wei
HPHongxu Pu
Hongxu Pu
RPRenpeng Peng
Renpeng Peng
XSXuying Sun
Xuying Sun
Osteoarthritis (OA), the most common chronic inflammatory joint disease, is characterized by progressive cartilage degeneration, subchondral bone sclerosis, synovitis, and osteophyte formation. Metformin, a hypoglycemic agent used in the treatment of type 2 diabetes, has been evidenced to have anti-inflammatory properties to treat OA. It hampers the M1 polarization of synovial sublining macrophages, which promotes synovitis and exacerbates OA, thus lessening cartilage loss. In this study, metformin prevented the pro-inflammatory cytokines secreted by M1 macrophages, suppressed the inflammatory response of chondrocytes cultured with conditional medium (CM) from M1 macrophages, and mitigated the migration of M1 macrophages induced by interleukin-1ß (IL-1ß)-treated chondrocytes in vitro. In the meantime, metformin reduced the invasion of M1 macrophages in synovial regions brought about by the destabilization of medial meniscus (DMM) surgery in mice, and alleviated cartilage degeneration. Mechanistically, metformin regulated PI3K/AKT and downstream pathways in M1 macrophages. Overall, we demonstrated the therapeutic potential of metformin targeting synovial M1 macrophages in OA.

12 May 2023 in International Immunopharmacology
Verified
Journal Article
Open access
KWKang Wei
Kang Wei
ZSZixing Shu
Zixing Shu
HPHongxu Pu
Hongxu Pu
HXHuanhuan Xu
Huanhuan Xu
SLSong Li
Song Li
TMTian Ma
Tian Ma
The chronic articular disease osteoarthritis (OA) is characterized by osteophyte generation, subchondral bone remodeling, and cartilage deterioration. Low levels of H2S catalyzed by cystathionine-γ-lyase (CSE) encoded by Cthhas neuroprotective, cardioprotective, anti-apoptotic, and anti-inflammatory effects thus, Cth is being developed as a potential therapy for the management of the pathogenesis and symptoms of osteoarthritis. Single-cell RNA sequencing (scRNA-seq) and immunohistochemistry of human cartilage revealed that the expression of CTH was decreased in OA patients. We found that Cthoverexpression decrease IL-1β-induced overactivation of the NF-κB signaling pathway. In vivo, Cthoverexpression relieved pain response and cartilage damage in the anterior cruciate ligament transection (ACLT) rat model. In vitro, CSE alleviated chondrocytes catabolism, inflammation, apoptosis, and senescence, and suppressed the NF-κB pathway. We postulate that CSE has therapeutic effects in suppressing inflammation and degeneration in OA and should be further investigated clinically.

3 October 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
HPHongxu Pu
Hongxu Pu
LDLanping Ding
Lanping Ding
PJPinhui Jiang
Pinhui Jiang
GLGuanghao Li
Guanghao Li
KWKai Wang
Kai Wang
XGXin Gan
Xin Gan
Bone immunity represents a dynamic interface where skeletal homeostasis intersects with systemic immune regulation. We synthesize emerging paradigms by contrasting two functionally distinct microenvironments: the marrow cavity, a hematopoietic and immune cell reservoir, and cancellous bone, a metabolically active hub orchestrating osteoimmune interactions. The marrow cavity not only generates innate and adaptive immune cells but also preserves long-term immune memory through stromal-derived chemokines and survival factors, while cancellous bone regulates bone remodeling via macrophage-osteoclast crosstalk and cytokine gradients. Breakthroughs in lymphatic vasculature identification challenge traditional views, revealing cortical and lymphatic networks in cancellous bone that mediate immune surveillance and pathological processes such as cancer metastasis. Central to bone immunity is the neuro–immune–endocrine axis, where sympathetic and parasympathetic signaling bidirectionally modulate osteoclastogenesis and macrophage polarization. Gut microbiota-derived metabolites, including short-chain fatty acids and polyamines, reshape bone immunity through epigenetic and receptor-mediated pathways, bridging systemic metabolism with local immune responses. In disease contexts, dysregulated immune dynamics drive osteoporosis via RANKL/IL-17 hyperactivity and promote leukemic evasion through microenvironmental immunosuppression. We further propose the “brain–gut–bone axis” as a systemic regulatory framework, wherein vagus nerve-mediated gut signaling enhances osteogenic pathways, while leptin and adipokine circuits link marrow adiposity to inflammatory bone loss. These insights redefine bone as a multidimensional immunometabolic organ, integrating neural, endocrine, and microbial inputs to maintain homeostasis. By elucidating the mechanisms of immune-driven bone pathologies, this work highlights therapeutic opportunities through biomaterial-mediated immunomodulation and microbiota-targeted interventions, paving the way for next-generation treatments in osteoimmune disorders.

13 November 2025 in International Immunopharmacology
Verified
Journal Article
Open access
LCLiangxi Chen
Liangxi Chen
HWHanling Wu
Hanling Wu
RRRanyue Ren
Ranyue Ren
YZYayun Zhang
Yayun Zhang
ZZZiwei Zhu
Ziwei Zhu
WXWei Xiong
Wei Xiong
Osteosarcoma represents the most prevalent primary malignant bone tumor in adolescents and young adults, with limited improvement in survival outcomes observed over recent decades. The development of personalized therapies remains challenging due to substantial molecular heterogeneity and the absence of robust prognostic models. In this study, we developed a machine learning-based consensus prognostic signature (MLPS) by integrating multi-cohort transcriptomic datasets and applying ten distinct machine learning algorithms. The resulting MLPS, comprising 11 prognostic genes, reliably stratified patients into high- and low-risk groups with significantly different survival outcomes and outperformed existing models (C-index = 0.862). The application of functional enrichment analyses revealed immune activation and inflammatory signaling in the low-risk group, consistent with a "hot tumor" phenotype. In contrast, the high-risk group exhibited upregulation of proliferative oncogenic pathways. Of particular significance is the observation that MLPS was able to suggest differential responses to chemotherapy and immunotherapy, thereby under-scoring its clinical utility. Single-cell analysis revealed that LGR4 expression is largely confined to malignant cell clusters. In vitro LGR4 knockdown significantly reduced osteosarcoma cell proliferation, migration, and PI3K-AKT-mTOR pathway activity, confirming its oncogenic role. These findings demonstrate the value of MLPS as a robust tool for prognostic assessment and individualized therapeutic decision-making in osteosarcoma.